T-cell receptors and compositions thereof for targeting mutant ras

Abstract

The present invention provides compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the present invention provides T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types. In certain aspects, the present invention provides multispecific (e.g., bispecific) antibodies comprising T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.

Dependencies are inferred from the claim text.